This award supports rapid implementation of clinical trials targeting diseases or conditions in FY26 PRMRP topic areas. It funds clinical trials across phases 0 to 3, including a planning phase for regulatory activities before trial start. Funding caps range from $800K for planning to $20M for phase 3 trials, with a maximum 4-year performance period. Animal studies are excluded, and preclinical work must be complete before award start.
Open to any type of entity, with no specific restrictions stated. Eligibility is unrestricted subject to additional clarifications.
